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Introduction: Sarcoidosis is a multisystemic disease of unknown etiology characterized by
the formation of immune granulomas in involved organs. The cytokine profile in inflamed
lesions of sarcoidosis is mainly determined by T helper 1 (Th1) cells. Interleukin 18 (IL-18)
is primarily a monocyte/macrophage-derived cytokine. IL-18 has been recently identified
as an IFNg-inducing factor. The cytokine plays an important role in the induction of Th1
response and it may be responsible for sarcoidosis progression.
The aim of the study was to assess the usefulness of IL-18 estimation in the sarcoidosis
diagnosis and the disease course prognosis.
Material and methods: The diagnosis of sarcoidosis was established in 88 patients (the
mean age of 38.1710.8 years). We measured IL-18 level in plasma and bronchoalveolar
lavage fluid (BALF) cell culture supernatant (CCS) using the enzyme-linked immunoassay
technique (ELISA). We also performed the flow cytometric analysis of BALF lymphocyte
phenotype. Statistica 5.0 and non-parametric tests: the Mann–Whitney U-test and the
Spearman correlation test, were used for statistical analysis.
Results: The patient group consisted of 55 subjects without acute symptoms of
sarcoidosis, 14 patients with acute Lo¨fgren syndrome and 19 subjects with Lo¨fgren
syndrome in the past. Lung hilar lymphadenopathy was diagnosed in 49 patients and lung
interstitial changes in 39 subjects. After 6-month-observation, 49 patients were in
remission, 20 subjects manifested persistent disease and 19 patients had sarcoidosis
progression. Plasma IL-18 level was significantly (Po0.0001) higher in sarcoidosis patients
(3837250 pg/ml) than in control subjects (146772 pg/ml). Plasma IL-18 level was similar
both in subjects with Lo¨fgren syndrome and in other patients. However, IL-18 level in BALF
CCS was significantly (Po0.05) lower in Lo¨fgren syndrome patients than in subjects
without acute manifestation of the disease. The highest IL-18 level in plasma was found in
patients with disease progression, in subjects with lung interstitial changes and in patientsElsevier Ltd. All rights reserved.
h State Committee for Scientific Research, Grant No. 3P0 5B 05 124.
742 52 40; fax: +48 81 740 04 02.
lin.pl (R. Kieszko).
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Interleukin-18 in sarcoidosis 723with extrapulmonary manifestation of the disease. We observed a positive correlation
between plasma IL-18 level and the percentage of BALF lymphocytes (R ¼ 0.202, P ¼ 0.06)
as well as the percentage of activated HLA DR+T cells (R ¼ 0.23, Po0.05). There was a
negative correlation between the IL-18 level in BALF CCS and the percentage of BALF CD3-
positive and CD4-positive lymphocytes (R ¼ 0.27, 0.23, Po0.05).
Conclusion: IL-18 may play a significant role in the prolongation of sarcoidosis course. Its
estimation may become a good prognostic factor, which should be analyzed together with
other factors useful in sarcoidosis monitoring.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a systemic granulomatous disease of unknown
origin that predominantly affects the lung. Lymphocytic
alveolitis and non-caseating, epithelioid granulomas
with the predominance of CD4+Th cells and macrophages
are characteristic of sarcoidosis. These cells release
chemokines and cytokines that lead to cellular proliferation
and granuloma formation. The cytokine profile of
active sarcoidosis is characterised by T helper 1 (Th1)
prevalence.1
Interleukin 18 (IL-18) is a pleiotropic cytokine involved in
the polarization of T-cell responce. There are multiple
sources of IL-18: macrophages, keratinocytes, dendritic
cells, Kupffer cells and airway epithelial cells. IL-18 is a
cytokine of 18 kDa, which is synthesized as an inactive
precursor molecule. IL-18 stimulates cytokine production by
immunological cells, mainly Th and cytotoxic T cells as well
as NK cells. First studies on IL-18 highlighted its role in the
induction of IFN-g and IL-2 production, and therefore IL-18
was defined as an inducer of Th1 response and cytotoxicity.2
However, IL-18 was also reported to induce the production
of Th2-type cytokines, i.e. IL-4 and IL-13, by NK and T cells
in vitro.3
The expression of IL-18 is increased at sites of
chronic inflammation in infectious diseases, in a neoplasm
and in autoimmune disorders.4–6 These findings suggest
that an increased serum level and expression of IL-18
and its receptor might be involved in the pathogenesis of
different human diseases. Deregulation of pulmonary
inflammation with relative defect in Th1 response is
hypothesized as a mechanism leading to airway diseases in
cystic fibrosis, and is connected with a decreased IL-18
expression in bronchoalveolar lavage fluid (BALF) cells and
peripheral blood mononuclear cells in cystic fibrosis
patients.7
Some studies have demonstrated an increased expression
of IL-18 in active sarcoidosis.8 IL-18 is produced by BALF
cells of sarcoidosis cases. IL-18 expression has been also
reported to be increased in airway epithelial cells of
sarcoidosis patients.9 Synergistically with IL-12, IL-18 can
induce IFN-g production without TcR engagement in Th1
cells and non-polarized T cells, and induces IFN-g release in
macrophages, B cells, dendritic cells and NK cells of
sarcoidosis patients.8 Moreover, the proportion of BALF
CD4+ and PB CD4+Tcells expressing IL-18 receptor alfa chain
(IL-18Ra) is significantly increased in patients with sarcoi-
dosis compared to control subjects.10 In sarcoidosis, IL-18
may also act as an important factor regulating the IL-2 geneexpression, via a transcription factor activation, leading to T
cell activation.11 Recently, Kelly and co-workers12 postu-
lated that Gram-negative bacteria, which have survived in
the airways of sarcoidosis patients, may contribute to Th1
response by up-regulating the IL-18 expression.
Only a limited number of studies have focused on the
relationship between serum IL-18 levels and clinical status
of sarcoidosis.13–15 Recently, it has been reported that IL-18
levels are increased in serum and BALF of patients with
active sarcoidosis. Patients having positive 67Ga scan had
higher serum IL-18 levels compared with those with negative
results. The level of IL-18 significantly correlated with the
activity of serum lysozyme, but not with the result of
pulmonary function tests.13
However, no study has yet assessed the usefulness of IL-18
measurement in serum and BALF cell culture supernatant
(CCS) in the identification of the patients with worse
prognosis of sarcoidosis and extrathoracic extend of the
disease.Material and methods
Study population
The study population comprised 88 patients (the mean age
of 38.1710.8 years; 44 female and 44 male subjects) with
newly diagnosed sarcoidosis. The patients were diagnosed in
Pulmonary Department from February 2004 to February
2005 and observed to February 2006. The diagnosis of
sarcoidosis was established using defined criteria including
histopathological confirmation. None of the patients re-
ceived steroid therapy at the time of bronchoscopy. The
assessment of the disease was based on clinical features,
chest X-ray and computed tomography, lung function tests,
abdomen ultrasonography, ophthalmologic investigation,
bronchoscopy with BAL and routine blood tests. The severity
of the disease was assessed on the basis of clinical,
radiological and pulmonary function data. Lo¨fgren syndrome
was manifested in 33 patients: 14 patients with acute
manifestations and 19 patients with acute signs in the past
but not at the moment of diagnosis and clinical assesment
(the mean age of 35.479.14 years). In the second
mentioned Lo¨fgren group, the acute symptoms of sarcoidosis
receded from two to three weeks before diagnosis. Twenty
patients presented insidious onset of the disease; 23
patients had acute symptoms of disease other than Lo¨fgren
syndrome (fatigue, weigh loss, breathlessness, cough,
fever); 49 patients (the mean age of 35.6711.7 years)
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Table 1 Clinical characteristic of examined patients.
Characteristics Patients Female/male Age (years)
Control N ¼ 10 5/5 40.0718.38
Subjects N ¼ 88 N ¼ 44/44 38.1710.8
Subjects with Lo¨fgren syndrome N ¼ 33 (37.5%) N ¼ 24/9 35.479.1
Subjects without Lo¨fgren syndrome N ¼ 55 (62.5%) N ¼ 20/35 38.5711.1
Chest X-ray stages I N ¼ 49 (55.7%) N ¼ 24/25 35.6711.7
Chest X-ray stages II/III N ¼ 39 (44.3%) N ¼ 20/19 41.4711.8
Clinical outcome
Remission N ¼ 49 (55.7%) N ¼ 29/20 36.378.2
Stable disease (n, %) N ¼ 20 (22.7%) N ¼ 8/12 39.2714.3
Progression (n, %) N ¼ 19 (21.6%) N ¼ 7/12 41.2711.0
R. Kieszko et al.724showed bilateral hilar lymphadenopathy in chest X-ray
examination. In 39 patients (the mean age of 41.4711.8
years) interstitial infiltration with or without hilar lympha-
denopathy (radiological stage II or III) were demonstrated.
We made a distinction between the self-limiting clinical
course radiographic stage I, and the stage II or III with high
probability of disease progression (Table 1).
All but one patient had intrathoracic manifestation of
sarcoidosis. In 36 patients extrathoracic lesions were
present (hepar, spleen, abdominal lymph nodes, skin lesions
other than erythema nodosum, eye involvement, kidneys,
salivary glands, central nervous system).
Pulmonary function tests were performed according to
the European Respiratory Society recommendations. Impair-
ment in a lung function test was defined as restriction:
forced expiratory volume in 1 s (FEV1) and vital capacity (VC)
o80% of predictive value, or obstruction: FEV1/VC ratio
o0.7. Diffusing capacity of the lung for carbon monoxide
(DLCO) o80% of predictive value was regarded as an
abnormality in gas exchange.
The follow-up (clinical investigation, chest X-ray and lung
function tests) was performed every 3 months. On the basis
of a 1–2-year follow-up, the patients were divided into the
group with spontaneous remission (the remission group
consisted of 49 patients), the group with long standing
disease with no need of treatment (the stable disease
group—20 patients), and the group with disease progression
and/or need of steroid treatment (the progression
group—19 patients). The decision to start steroid therapy
was based on the presence of severe systemic symptoms,
lung function deterioration, progression seen in chest X-ray
or CT scans (Table 1).
The research project was approved by the Bioethic
Committee of the Medical University of Lublin in accordance
with the Guidelines for Good Clinical Practice.Control group
The control group consisted of 10 non-smoking volunteers.
None of them had any evidence of lung disease and
concomitant therapy. For the estimation of plasma IL-18
level only blood samples were taken.BAL procedure and BALF cell preparation and
culture
Bronchoscopy and BAL were performed at the start of
diagnosis as described previously16 using Pentax EPM 3300
equipment. A bronchoscope was passed transorally under
the adequate topical anesthesia with 4% lidocaine. The
standard protocol of fiberoptic performance was applied to
all patients.
BAL fluid (BALF) was obtained by standard washing of the
middle lobe with seven 20-ml aliquots of pre-warmed sterile
0.9% saline. The pooled BALF specimen, except for the first
bronchial fraction, was carefully mixed, strained through a
double layer of nylon gauze and centrifuged to obtain cell
pellet. Cells were washed twice with phosphate-buffered
saline (PBS) and counted in Neubauer chamber. Cells pellet
was resuspended in RPMI 1640 medium.
A total of 106 cells per ml were cultured in RPMI 1640
medium supplemented 2mM L-glutamine and antibiotics
without any stimulation in 6-well plates (Nunc, Denmark) for
24 h at 37 1C under 5% CO2. CCS was centrifuged at 400g and
stored at 80 1C for cytokine level measurement.
Flow cytometry technique and monoclonal antibodies
(Simultest, Becton Dickinson, USA) were used for immuno-
phenotyping of BALF mononuclear cells. Cells were incu-
bated for 20min at room temperature and immediately
analyzed in flow cytometer FACS Calibure (Becton Dickinson,
USA).
Asessement of IL-18 in plasma and BALF CCS
Blood samples were taken on the day of bronchoscopy. The
determination of IL-18 levels in plasma and BALF CCS was
performed using an enzyme-linked immunoassay technique
(ELISA), the commercial Quantikine Human IL-18 kit (R&D
System, USA) and the ELx 800 equipment (Bio-Tek Instru-
ments, USA).
Statistical analysis
The data are presented as the mean7SEM. Pearson w2
analysis was used to test the differences between different
groups of patients in the distributions of gender and age.
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test was used for the comparison of unpaired group data.
The Wilcoxon-matched pairs test was applied for comparing
two variables. In a correlation assessment, the Spearman
correlation test was used. A level of Po0.05 was assigned as
significant.Results
Plasma and BALF CCS IL-18 levels in sarcoidosis
patients
Plasma IL-18 level in sarcoidosis patients was significantly
higher (Po0.0001) compared to the control group
(383.247250.2 pg/ml versus 146.61771.97 pg/ml) (Fig. 1).
BALF CCS IL-18 level in the whole group of patients was
86.17799.85 pg/ml.
In comparison with patients with different radiological
stages, plasma IL-18 concentration was slightly higherTable 2 BALF immunological analysis in patients with differen
Lo¨fgren syndrome
patients
Patients witho
Lo¨fgren syndr
Lymphocytes (%) 42.35721.74 42.41720.86
Macrophages (%) 52.83722.96 52.69720.91
T lymphocytes (%) 92.6473.21 89.5975.39**
B lymphocytes (%) 0.9770.98 1.4271.24
NK cells (%) 2.4671.28 4.5373.38**
Th lymphocytes (%) 80.4577.29 72.9711.33*
Tc-s lymphocytes (%) 10.2275.93 15.9279.69*
CD4:CD8 ratio 11.4777.42 6.8174.97**
Activated T cells HLA
DR+ (%)
51.81714.31 53.09714.15
*Po0.05, **Po0.005.
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Figure 1 Plasma IL-18 level in patients with different course
of sarcoidosis.(P ¼ 0.13) in stages II/III (440.897308.32 pg/ml) than in
stage I (337.178 7183.08 pg/ml). We found insignificantly
(P ¼ 0.067) lower IL-18 concentration in BALF CCS from
patients with Lo¨fgren’s syndrome (63.085793.85 pg/ml)
compared to non-Lo¨fgren patients (101.837108.85 pg/ml).
Moreover, the percentage of BALF CD4-postive cells and
the value of CD4:CD8 ratio were significantly higher in
patients with Lo¨fgren’s syndrome compared to the subjects
without acute symptoms (Po0.001) (Table 2).
A significant positive correlation between plasma IL-18
level and the percentage of BALF CD4-positive cells was
noticed in Lo¨fgren’s syndrome patients (R ¼ +0.41,
Po0.05). Moreover, there was a significant positive correla-
tion between the plasma IL-18 level and the percentage of
activated HLA DR-postive T lymphocytes from BALF in
patients without Lo¨fgren’s syndrome (R ¼ 0.33, Po0.01).Pulmonary function
The mean percentages of predictive values of VC, FEV1,
FEV1/VC, TLC and DLCO in the sarcoidosis group were within
a normal range. The patients from the progression group had
significantly lower VC (Po0.05), TLC (Po0.01), and FEV1/
VC (Po0.05) values in comparison with the patients from
the remission group (Table 3). There was no significant
correlation between plasma and BALF CCS IL-18 levels, and
PFT parameters.t manifestation of sarcoidosis.
ut
ome
Patients in I stage of
sarcoidosis
Patients in II or III stage
of sarcoidosis
42.05721.89 42.84719.98
53.91722.19 51.24720.34
91.0174.46 89.5575.75
1.2471.01 1.471.39
3.2672.02 4.9473.93*
* 74.09710.04 71.98711.02*
12.8278.8 16.5479.38*
9.4376.79 6.1974.3**
49.71713.3 56.54714.35*
Table 3 The PFT results in the patients with different
course of sarcoidosis.
All patients group Remission group Progression group
FEV1 86.19715.5 88.22715.71 83.00714.43
VC 88.87711.42 92.0978.26 84.07712.24*
FEV1/VC 82.69713.29 84.92713.17 76.17710.86*
TLC 89.47712.18 92.31712.05 83.1379.00**
DLCO 91.37715.18 92.47713.01 87.53718.55
*Po0.05, **Po0.01.
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Table 4 The level of plasma and BALF CCS IL-18 in patients with different manifestation of sarcoidosis.
Control Lung sarcoidosis Extrathoracic sarcoidosis
with one organ affected
Extrathoracic sarcoidosis with
two or more organs affected
Plasma IL-18 146.61771.97 325.127193.07** 407.167218.48 575.997419.53*
BALF CCS IL-18 N.D. 88.54787.16 68.75793.95 86.307118.49
N.D.: not done.
*Po0.05, **Po0.0001.
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Figure 2 Plasma IL-18 level in patients with and without
extrapulmonary manifestation of sarcoidosis.
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Figure 3 Correlation between the percentage of BALF
lymphocytes and plasma IL-18 level in sarcoidosis patients.
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Figure 4 Correlation between the percentage of BALF HLA DR-
positve T lymphocytes and plasma IL-18 level in sarcoidosis
patients.
R. Kieszko et al.726Extrathoracic manifestations
Plasma but not BALF CCS IL-18 level was slightly higher in all
patients with extrathoracic sarcoidosis in comparison to
patients only with lung involvement (458.747298.75 and
74.017100.13 versus 325.127193.07 and 88.54787.16,
respectively). Patients with two or more organs affected
had significantly higher plasma IL-18 level compared to
patients with lung sarcoidosis (575.997419.53 versus
325.127193.07, Po0.05) (Table 4, Fig. 2). One female
patient with extrathoracic sarcoidosis with three affected
organs had extremely high level of plasma IL-18 (1699pg/ml).Correlations between IL-18 level and BALF markers
of activity
The percentages of BALF lymphocytes and activated HLA DR-
positive T cells were significantly higher in patients with
further sarcoidosis progression and in treated subjects in
comparison to patients with disease remission (Po0.01).
The percentage of BALF macrophages was, however,
significantly lower in subjects with disease progression than
in patients with spontaneous remission. There was a slight
positive correlations between plasma IL-18 level and the
percentages of BALF lymphocytes (R ¼ 0.2, P ¼ 0.06), of
CD4+lymphocytes (R ¼ 0.189, P ¼ 0.08), and of activated
HLA DR+T lymphocytes (R ¼ 0.23, Po0.05) (Figs. 3 and 4).There was a negative correlation between IL-18 level in
BALF CCS and the percentage of BALF CD3-positive and CD4-
positive lymphocytes (R ¼ 0.27, 0.23, Po0.05).Plasma IL-18 as a predictive marker
There were no significant differences in IL-18 levels in
plasma and BALF CCS of patients with different clinical
course of sarcoidosis. However, we found a tendency to
lower BALF CCS and plasma IL-18 levels in patients with
remission in comparison with patients with further disease
progression, and those who needed steroid treatment
(Fig. 1). The progression of sarcoidosis was observed more
frequently in patients with II/III radiological stage (n ¼ 14,
35.9%) of disease than in subjects in I radiological stage
ARTICLE IN PRESS
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of patients, the levels of BALF CCS and plasma IL-18 were
similar in subjects with I radilogiocal stage of the disease
and in patients with II/III stage.Discussion
An increased expression of IL-18 in the lung may be involved
in the pathogenesis of several lung diseases including
tuberculosis, idiopatic pulmonary fibrosis (IPF) and sarcoi-
dosis. Recently, it has been reported that IL-18 levels are
increased in plasma and lung specimens of patients with IPF
and advanced tuberculosis.17–19 Inomata and coworkers
reported that the levels of circulating IL-18 and osteoponin
were in close relationship with radiological extend and
clinical severity of tuberculosis.19
Some investigators have reported that IL-18 has been
increased in the serum and BALF of sarcoidosis patients. We
found significantly elevated serum IL-18 level in the
sarcoidosis patients compared to the control group. Plasma
IL-18 levels in our sarcoidosis group (383 pg/ml) are similar
to the results of other studies: 372.1 pg/ml in the Fukami’s
study,20 419.4 pg/ml in the Shigehara’s study13 and 239
pg/ml in the Tanaka’s investigation.14 Our findings concern-
ing higher plasma IL-18 level in patients with multiorgan
sarcoidosis are in concordance with the recent study of
Fukami and co-workers.20 The authors investigated the IL-18
gene expression and protein production within granuloma-
tous lesions in sarcoidosis. Western blot analysis and
immunohistochemistry showed that IL-18 was highly pro-
duced by inflammatory cells in sarcoid granulomas of
muscular sarcoidosis, resulting in an increased concentra-
tion of IL-18 in serum of patients with sarcoidosis. Serum
IL-18 might be leaking from the local granulomas and may
reflect disease activity. On the other hand, it might be
possible that the production of IL-18 by peripheral blood
mononuclear cells is enhanced in sarcoidosis.
Findings of Hauber and co-workers21 also support the
hypothesis that sarcoid granulomas are the main source of
IL-18 production and secretion. The authors found a
decreased IL-18 expression in BALF cells of sarcoidosis
patients, however, IL-18 secretion by BALF cells with and
without LPS stimulation did not differ between control and
sarcoidosis patients. The authors concluded that BALF cells
are not the main source of an elevated IL-18 level in BALF.
Recently, increased expression of IL-18 has been shown in
sarcoid and asthma airway epithelium.9,21
Generally, sarcoidosis patients have a favorable clinical
prognosis. More than 60% of patients have spontaneous
remission. Severe extrapulmonary manifestation (heart,
central nervous system, liver) is seen in 4–7% of patients,
but this percentage increases with disease duration.
Systemic steroid therapy is needed in the cases with life-
threatening organ involvement, renal dysfunction, severe
hepatic dysfunction, palpable splenomegaly, and disfiguring
skin lesions. Up to 5% of sarcoidosis patients die of the
disease, most frequently from neurosarcoidosis, cardiac
involvement and respiratory insufficiency.1,22 Early detec-
tion of live-threatening organ involvement could improve
clinical management of the disease.The usefulness of BALF cell analysis in the prediction of
sarcoidosis outcome is still not established. The intensity of
lymphocytic alveolitis and the value of the CD4/CD8 ratio
are the most frequently investigated BALF parameters.
Some studies have shown that basing on these BALF
parameters it has been possible to predict the deterioration
of the sarcoidosis course. Numerous studies have found that
the disease course in patients with an initial high percentage
of BALF lymphocytes and a high value of the CD4/CD8 ratio
has improved.23,24 However, other investigations have shown
that BALF lymphocyte count is not significant in the course
of sarcoidosis.25 In our study, we found significantly higher
percentages of BALF lymphocytes and activated HLA DR-
positive T cells in patients with further sarcoidosis progres-
sion and the need of treatment in comparison with patients
with disease remission. Our findings concerning the sig-
nificance of the high percentage and the count of BALF HLA
DR-positive T cells in the prediction of sarcoidosis outcome
are in agreement with the results of Suzuki’s investigation.26
Plasma IL-18 seems to positively correlate with the value
of these BALF paramters. Moreover, the highest levels of
IL-18 in plasma and BALF CCS were found in patients with
further sarcoidosis progression. These findings support the
hypothesis that plasma IL-18 may have a minor influence on
sarcoidosis course. Moreover, our study seems to confirm the
crucial role of extrapulmonary granuloma formation in an
apperance of increased level of plasma IL-18.
Many cytokines, their receptors and gene polymorphisms
have been investigated as potential markers of activation or
prognostic factors in sarcoidosis. Only a few of them may
become useful in a clinical practice. The estimation of IL-18
levels may be helpful in the analysis of disease activity and
in the prognosis of sarcoidosis course. Such an analysis
should be taken into account especially in patients
suspected of an extrapulmonary sarcoidosis manifestation.References
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